Live feed16:01:00·1422dPRReleasevia QuantisnowRigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid LeukemiaByQuantisnow·Wall Street's wire, on your screen.FMTX· Forma Therapeutics Holdings Inc.RIGL· Rigel Pharmaceuticals Inc.Health Care
